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Abstract
How parathyroid hormone (PTH) increases bone mass is unclear but understanding this
phenomenon is significant to the improvement of osteoporosis therapy. Nmp4/CIZ is a
nucleocytoplasmic shuttling transcriptional repressor that suppresses PTH-induced osteoblast gene
expression and hormone-stimulated gains in murine femoral trabecular bone. To further
characterize Nmp4/CIZ suppression of hormone-mediated bone growth we treated 10 wk-old
Nmp4-knockout (KO) and wild-type (WT) mice with intermittent human PTH (1-34) at 30μg/kg/
day or vehicle, 7 days/wk, for 2, 3, or 7 wks. Null mice treated with hormone (7 wks) gained more
vertebral and tibial cancellous bone than WT animals paralleling the exaggerated response in the
femur. Interestingly, Nmp4/CIZ suppression of this hormone-stimulated bone formation was not
apparent during the first 2 wks of treatment. Consistent with the null mice enhanced PTH-
stimulated addition of trabecular bone these animals exhibited an augmented hormone-induced
increase in serum osteocalcin 3 wks into treatment. Unexpectedly the Nmp4-KO mice displayed an
osteoclast phenotype. Serum C-terminal telopeptides, a marker for bone resorption, was elevated
in the null mice, irrespective of treatment. Nmp4-KO bone marrow cultures produced more
osteoclasts, which exhibited an elevated resorbing activity, compared to WT cultures. The
expression of several genes critical to the development of both osteoblasts and osteoclasts were
elevated in Nmp4-KO mice at 2 wks but not 3 wks of hormone exposure. We propose that Nmp4/
CIZ dampens PTH-induced improvement of trabecular bone throughout the skeleton by transiently
suppressing hormone-stimulated increases in the expression of proteins key to the required
enhanced activity/number of both osteoblasts and osteoclasts.
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INTRODUCTION
Parathyroid hormone (PTH) therapy is the only osteoporosis treatment that restores bone to
the aged skeleton, however its expense makes it the least cost-effective (1, 2). The
development of shorter PTH-based treatments yielding similar efficacy as the longer-term
therapy will improve its cost-benefit ratio (2) but this requires a better understanding of the
mechanisms underlying the PTH anabolic response.
Data on the self-limiting pathways to PTH action, inherent to all endocrine response loops,
are lacking and it is these molecules that may provide the best pharmaceutical targets for
improving hormone efficacy and cost-effectiveness (3). For example, as PTH activates the
osteoblast generation of cAMP and the enhanced expression of RUNX2 it simultaneously
stimulates phosphodiesterase activity (4) and Smurf1-mediated RUNX2 proteasomal
degradation (5).
We recently demonstrated that disabling the nucleocytoplasmic shuttling transcription factor
Nmp4/CIZ (nuclear matrix protein 4/cas interacting zinc finger protein) in mice enhances
the skeletal response to anabolic PTH (6) suggestive of a significant role in the hormone’s
self-limiting pathways. Ten wk-old Nmp4-knockout (KO) mice treated with intermittent
PTH for 7 wks exhibited an augmented increase in femoral trabecular bone compared to
wild-type (WT) mice without compromising the hormone-stimulated increases in bone
mineral density and content throughout the skeleton (6).
The ubiquitously expressed Nmp4/CIZ appears to act as a general repressor of anabolic bone
growth, in part, by suppressing the transcription of genes that support the development of
the osteoblast phenotype, including the pro-alpha1(I) chain (Col1a1) and the Mmp-13
promoters (3, 7, 8). This trans-acting protein suppressed the PTH induction of rat Mmp-13
transcription in UMR-106-01 osteoblast-like cells via its binding to a PTH-responsive
element in the 5′ regulatory region of the gene (8) but whether Nmp4 represses the hormone
responsiveness of other tissues has not been reported.
In the present study we determined that Nmp4/CIZ suppressed the PTH-stimulated
improvement of trabecular bone throughout the mouse skeleton and was not site-specific as
is common in other mouse models (9, 10). Most surprisingly, we discovered that the null
mice have an osteoclast phenotype. The analysis of serum biochemistry, bone
histomorphometry, bone mRNA expression profiles, and osteoclast cell culture, suggest that
the numbers and activities of both osteoblasts and osteoclasts are enhanced in the Nmp4-KO
mice due, in part, to a transient de-repression of key transcription factors and signaling
proteins common to pathways critical for the development and hormone-responsiveness of
both cell types.
MATERIALS AND METHODS
Mice
Construction of the Nmp4-KO mouse, its backcrossing six generations onto a C57BL/6J
background, and the baseline phenotype, has been described (6). As in our previous study
wild-type C57BL/6J mice from The Jackson Laboratories (Bar Harbor, ME) were used as
controls (6). Experiments designed to compare the response of WT and Nmp4-KO mice to
PTH compensated for any differences in genetic and environmental factors (see Statistical
Analyses). Our local Institutional Animal Care and Use Committee approved all
experiments and procedures involving the production and use of the experimental mice
described in this study.
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PTH treatment regimen
Prior to the start of an experiment 8 wk-old female WT and Nmp4-KO mice were given
100μl sterile saline by subcutaneous (sc) injection once daily to acclimatize them to
handling. At 10 wks of age, mice were sorted into four groups based on equivalent mean-
group-body weight. The four treatment groups included 1) vehicle-treated WT; 2) PTH-
treated WT; 3) vehicle-treated Nmp4-KO and 4) PTH-treated Nmp4-KO. Mice were injected
sc with human PTH 1-34 (hPTH(1-34), Bachem Bioscience Inc, PA) at 30μg/kg/day, daily
or vehicle control (0.2% BSA/0.1% 1.0 mN HCl in saline, Abbott Laboratory, North
Chicago, IL) for the times specified in the Results. Additionally, animals were administered
by intraperitoneal injection calcein green (20 mg/kg, Sigma-Aldrich, St Louis, MO) and
alizarin red (25 mg/kg, Sigma-Aldrich) 6 days and 3 days before euthanasia, respectively.
Dual energy x-ray absorptiometry (DEXA)
Bone mineral content (BMC; g), areal bone mineral density (aBMD; mg/cm2), and body
weight were measured weekly (8 wks to 12 wks of age). The BMC and aBMD were
obtained for the post-cranial skeleton by dual-energy X-ray absorptiometry (DEXA) using
an X-ray PIXImus mouse densitometer (PIXImus II; GE-Lunar Corp., Madison, WI) as
previously described (6). We report whole body (WB), femur, tibia, and spine BMD and
BMC.
Micro computed tomography (μCT)
Vertebrae, femurs, and tibiae were dissected from the WT and Nmp4-KO animals after
euthanasia, the connective tissue and muscle removed, and the bones stored in 10% buffered
formalin at 4°C. After 48 hr the bones were transferred to 70% ethanol and stored at 4°C
until analyzed. We have previously described our methodology for assessing the trabecular
microarchitecture at the distal femoral metaphysis and within the 5th lumbar vertebra using
the desktop micro-computed μCT 20 tomographer (Scanco Medical AG, Bassersdorf,
Switzerland; [6, 9]). Cancellous bone of the tibia was evaluated by scanning the proximal
20% of each tibia at 9 μm resolution. A microfocus X-ray tube with a focal spot of 10 μm
was used as a source. Precisely 90 micro-tomograph slices were acquired per bone
beginning 1 mm from the epiphysis and extending distally 1.53 mm using a slice increment
of 17 μm. For each slice, 600 projections were taken over 216° (180° plus half of the fan
angle on either side). Proximal tibia stacks were reconstructed to the 3rd dimension using a
standard convolution-backprojection procedure with a Shepp-Logan filter using a threshold
value of 275. The Scanco software permitted evaluation of tibial, femoral and vertebral
trabecular bone volume per total volume (BV/TV, %), connectivity density (Conn.D,
mm−3), structure model index (SMI), trabecular number (Tb.N, mm−1), trabecular thickness
(Tb.Th, mm), and spacing (Tb.Sp, mm) from the 3D constructs. To evaluate cortical
architecture, a single slice was taken through the midshaft femur (simply by measuring the
number of slices for the whole femur and dividing by 2), and the cortical area (CA, mm2),
marrow area (MA, mm2), and the total area (TA, mm2) were calculated (6). Additionally,
the moments of inertia, the resistance of the bone to a bending load, were derived from these
data. These parameters included the greatest (IMAX, mm4) and smallest (IMIN, mm4) flexural
rigidity as well as the polar moment of inertia (J, mm4), which is the torsional and bending
rigidity around the neutral axis of the bone and perpendicular to the x- and y-axes passing
through the center of mass (11).
Quantitative real-time PCR (qRT-PCR) analysis
Femoral or tibial RNA from mice that had been treated with intermittent PTH or vehicle for
2 wks or 3 wks was harvested either 1 hr or 24 hrs after the last injection. The harvesting,
processing, and analysis protocols for qRT-PCR analysis have been described (6, 9). Real-
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time PCR primers and probes were obtained from Assays-on-Demand™ (Applied
Biosystem, Foster City CA, see Table 1). The ΔΔCT method was used to evaluate gene
expression between WT and KO animals using Rplp2 as the normalizer after screening
several housekeeping gene candidates. The coefficient of variation of Rplp2 was typically 2–
3% between all samples. Normalization against internal control genes is most frequently
used because it can control all variables including cell number (12, 13). The data represent
the mean ± standard deviation from at least 6 mice per genotype.
Bone histomorphometry
Femurs were removed from the WT and Nmp4-KO animals after euthanasia and fixed as
described above. The anterior face of the epiphyseal plate was cut to expose the marrow
cavity. Samples were then dehydrated with graded alcohols, embedded in methyl-
methacrylate, sectioned (4μm) with a Leica RM2255 microtome (Leica Microsystems,
Wetzlar, Germany), and mounted on standard microscope slides. All histomorphometric
parameters were obtained following ASBMR guidelines (14). Mineral apposition rate
(MAR), mineralizing surface (MS/BS) and bone formation rate (BFR), were obtained from a
0.03mm2 metaphyseal region of interest from 250μm to 1750μm below the growth plate
using ImagePro 3.1 software (Media Cybernetics, Bethesda, MD, USA). Some sections
were stained for tartarate resistant acid-phosphatase (TRAP). The number of TRAP-positive
(TRAP+) cells on the bone surface (TRAP+ cell N/BS) and the TRAP-stained surface to
bone surface (TRAP+ S/BS) were determined.
Serum biochemistry
Intact serum osteocalcin was measured using the sandwich ELISA BTI Mouse Osteocalcin
EIA Kit (Biomedical Technologies, Inc., Stoughton MA; [15]). Serum C-terminal
telopeptides (CTX) were determined using the RatLaps™ ELISA (Immunodiagnostic
Systems Inc., Scottsdale, AZ; [15]).
Osteoclast culture and activity
To compare the number of osteoclasts derived from Nmp4-KO and WT mice, bone marrow
was flushed from the long bones of 6–8 week-old animals. Cells were seeded into 24-well
culture dishes at an initial density of 2.1×105 cells/mm2 and cultured in alpha-MEM
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS (FBS, Hyclone, Logan Utah) and
20 ng/ml of recombinant human M-CSF (Peprotech, Rocky Hill, NJ) for 2 days and then
supplemented with 20 ng/ml of recombinant human M-CSF and 80 ng/ml of recombinant
human RANKL (Peprotech) for the duration of the experiment. The cell culture medium
was changed every third day until osteoclasts were visible. Once osteoclasts had formed, the
cells were fixed with 2.5% glutaraldehyde in phosphate buffered saline for 30 minutes at
room temperature, stained for TRAP (Sigma-Aldrich), and TRAP+, multinucleated (≥3)
cells were counted.
The osteoclast resorption activity of cells derived from the KO and WT mice was evaluated
using a standard pit assay (16). Bone marrow was isolated as above and plated into 6-well
culture dishes at 2×106 cells/well (2.1×105 cells/mm2). As detailed above, cells were
incubated in alpha-MEM containing 10% FBS and 20 ng/ml M-CSF for 2 days. The media
was removed and replaced with fresh media containing 20 ng/ml M-CSF and 80 ng/ml
RANKL for an additional 2–3 days. Mature osteoclasts were detached by trypsinization,
washed once, re-plated onto dentin slices (Immunodiagnostics Systems Inc, Fountain Hills,
AZ) and cultured for an additional 48 hrs in media containing 20 ng/ml M-CSF and 80 ng/
ml RANKL. Dentin slices were washed, incubated in 6% NaOCl for 5 min, and sonicated
for 20 s to remove cells. Resorption pits were stained with a solution containing 1%
toluidine blue and 1% sodium borate for 1 min, washed with water and air-dried. Pit surface
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area was quantified using the ImagePro 7.0 on a Leica DMI4000 with a 10X objective.
Results were normalized for osteoclast number, as determined by counting TRAP+ cells
containing 3 or more nuclei. Experiments were performed in triplicate and results represent
average pit area per dentin slice/OC number.
Statistical analyses
Statistical analysis was processed using JMP Version 7.0.1 (SAS Institute, Cary, NC).
Experiments designed to compare the response of WT and Nmp4-KO mice to PTH
compensated for any differences in genetic and environmental factors, i.e. the fact that WT
mice were not bred in-house was accounted for by our analyses. For example, the raw BMD
and BMC data were converted to % change (between 8 and 12 wks of age). Comparing
hormone-treated to vehicle-treated within each genotype for all the endpoint analyses
removed baseline differences from those factors and permitted analysis for genotype ×
treatment interactions, i.e. whether the WT and Nmp4-KO mice responded differently to
hormone for the parameter under consideration. We employed a two-factor ANOVA for
these analyses. If a genotype × treatment interaction was indicated the data were then
analyzed by a Tukey’s HSD post hoc test to determine significant differences between the
experimental groups. For the serum analysis experiment we used a repeated-measures
multivariate analysis of variance (MANOVA) to evaluate the raw longitudinal serum
osteocalcin and CTX levels over the 7 wk hormone treatment period. Additionally, we
converted the serum data to % change and analyzed with the two-factor ANOVA. The
genotype × time term for the raw longitudinal serum data is equivalent to the genotype term
for the % change data i.e. both terms indicate a difference in the rate of either osteocalcin/
CTX increase or bone accrual (for the BMD/BMC study) between the WT and null mice.
For some experiments, unpaired t-tests were employed as indicated. Data are presented as
mean ± SD unless otherwise indicated. Statistical significance was taken at p<0.05.
RESULTS
Nmp4-KO mice exhibited an enhanced PTH-induced acquisition of trabecular bone
throughout the skeleton compared to WT mice after 7 wks but not 2 wks of treatment
We previously showed that Nmp4-KO mice exhibited a significantly exaggerated PTH-
stimulated increase in femoral trabecular bone compared to WT mice after 7 wks of
hormone challenge (6); here we addressed whether Nmp4/CIZ represses PTH-induced
improvement in other parts of the skeleton and if this suppression is evident from the start of
the treatment regimen. Animals were treated with intermittent hPTH(1-34) 30μg/kg/day or
vehicle for 7 wks from 10 wks of age. Mice were sorted in the four treatment groups and the
cancellous architecture characterized as described in the Material and Methods. The Nmp4-
KO L5 vertebra BV/TV exhibited a more robust increase in response to 7 wks of PTH than
the WT BV/TV as demonstrated by a strong treatment effect and significant genotype ×
treatment interaction (Figure 1A). The PTH-induced change in vertebral morphology from a
rod-like to plate-like form was more pronounced in the null mice (SMI, Figure 1C).
Vertebral Tb Th was significantly enhanced in response to 7 wks of hormone in the null
mice but not in the WT animals (Figure 1E), whereas PTH had an equivalent impact on Tb
Sp (Figure 1F); a consequence of the fact that these parameters do not have a simple
reciprocal relationship (14). PTH had an equivalent impact on Conn D (Figure 1B) in the
genotypes. Finally, there was a strong genotype effect for all the measured vertebral
parameters consistent with the more robust trabecular architecture in the null mice (Figures
1A–1F). Typical μCT scans of L5 vertebra from mice treated with intermittent hormone or
vehicle for 7 wks are shown in Figure 1G.
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To evaluate the early hormone response of the L5 vertebra we compared bones from WT
and Nmp4-KO mice that had been treated with PTH or vehicle for 2 wks. The L5 vertebra
trabecular bone showed no improvement after 2 wks of hormone in either the WT or null
animals (Figure 1A–1F). However, there was a genotype effect for BV/TV, Conn D, SMI,
and Tb Th (Figures 1A, 1B, 1C, and 1E, respectively), thus the enhanced vertebral
trabecular architecture observed in the 17 wk-old null mice irrespective of treatment, was
apparent in these mice at 12 wks of age.
Nmp4/CIZ also repressed the hormone-induced increase in tibial cancellous bone (Figure 2).
The PTH-stimulated increase in tibial BV/TV after 7 wks of hormone was greater in the null
than the WT mice (Figure 2A). PTH increased tibial Tb N in both genotypes but
significantly more so in the null mice (Figure 2D) and the hormone-stimulated change in
tibial SMI was more pronounced in the null mice (Figure 2C). PTH had a comparable
positive effect on Conn D (Figure 2B), Tb Th, (Figure 2E), and Tb Sp (Figure 2F) in the WT
and null mice with 7 wks of treatment. Typical μCT scans of tibia from mice treated with
hormone or vehicle for 7 wks are shown in Figure 2G.
To evaluate the early hormone response of the tibia we compared bones from WT and
Nmp4-KO mice that had been treated with PTH or vehicle for 2 wks. Both genotypes
showed equal hormone-induced improvement of tibial BV/TV, Conn D, SMI, and Tb Th
during the initial 2 wks of treatment (Figures 2A, 2B, 2C, 2E). PTH failed to improve Tb N
and Tb Sp in both WT and null mice during this period of the regimen, however there was a
genotype effect for these two parameters indicating enhanced aspects of tibial architecture in
the null mice at 12 wks of age (Figure 2D & 2F).
Disabling Nmp4 had no impact on any aspect of the skeletal response to PTH (no genotype
× treatment interaction) during the first 2 wks of treatment including femoral cancellous
architecture (Table 2A), midshaft cortical architecture (Table 2B) and the percent change
skeletal BMD and BMC (Table 2C). Consistent with Nmp4 repressive action on bone
growth (6) genotype effects were observed for some of these parameters indicative of the
modestly enhanced skeletal phenotype of the null animals. Interestingly, the genotype
effects for WB BMC and femur and tibia BMD and BMC (Table 2C) indicated that the rate
of bone accrual was lower in the null mice over the four-week period of measurement
irrespective of treatment.
The enhanced PTH-stimulated increase in femoral trabecular bone observed in Nmp4-KO
mice occurred after 2 wks and before 7 wks of hormone exposure
Histological sections of the femoral spongiosa prepared for histomorphometry (Figure 3A)
confirmed our previous analysis using μCT (6) that the Nmp4-KO mice added more
cancellous bone in response to 7 wks of hormone treatment than WT mice. However, bone
formation rate parameters were not different between the null and WT mice at the end of
treatment and in fact were declining suggesting that PTH response was beginning to plateau
in both genotypes. MS/BS, proportion of bone surface undergoing mineralization, was
significantly decreased in both genotype treatment groups consistent with the declining
PTH-responsiveness (Table 2D). Additionally, we did not observe a significant hormone-
induced increase in bone formation rate (BFR) in either of the genotypes at this point in
treatment (Table 2D). Nevertheless, PTH equally enhanced the mineral apposition rate
(MAR) in both genotypes at this time point (Table 2D).
Our histomorphometric analysis of mice treated with PTH or vehicle for 7 wks included the
parameters of TRAP+ S/BS and TRAP+ N/BS, which provide an estimate of the size and
number of osteoclast precursors and mature osteoclasts normalized to bone surface. Clearly
the anabolic hormone treatment enhanced the absolute number of osteoclasts and the total
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osteoclast surface over bone in both genotypes as evident from the histological sections
(Figure 3B); normalizing these parameters to bone surface reveals that although both
parameters are elevated in the null mice the differences are not statistically significant
(Table 2D). However there were strong treatment effects, i.e. PTH significantly attenuated
the percent bone surface covered by TRAP+ cells and their number/surface (Table 2D).
Interestingly there was a genotype × treatment interaction for TRAP+ S/BS indicating that
hormone had a larger impact on the reduction of bone surface covered by osteoclasts in the
null mice than in the WT animals (Table 2D).
Nmp4-KO mice exhibited strikingly different serum osteocalcin and CTX profiles compared
to WT animals
Whole blood was collected and serum separated from the mice of the four treatment groups
at 10 wks of age (before initiation of treatment), 13 wks of age (3 wks of PTH/vehicle
treatment), and 17 wks of age (7 wks of PTH/vehicle treatment). The raw longitudinal data
and the % change data for osteocalcin, a standard marker for bone formation and osteoblast
number, revealed that null and WT mice had equivalent serum levels just prior to hormone
treatment but the Nmp4-KO mice exhibited a higher rate of increase over the hormone
treatment period (genotype × time interaction, longitudinal data; genotype interaction, %
change data) and exhibited an enhanced response to hormone (genotype × treatment
interaction, Figures 4A & 4B). Specifically, the null mice showed an enhanced and
sustained increase in osteocalcin after 3 wks of treatment while the WT animals showed a
peak at 3 wks of treatment followed by a decline by 7 wks of treatment (Figure 4A & 4B).
Serum C-terminal telopeptides (CTX), a marker for bone resorption, was significantly
elevated in the Nmp4-KO mice compared to the WT animals before and during the hormone
treatment period. CTX was elevated with PTH treatment in both genotypes but this increase
was not statistically significant (Figure 4C & 4D).
Bone marrow from Nmp4-KO mice yields more osteoclasts than marrow from WT mice and
the null osteoclasts exhibit an enhanced resorbing activity
To confirm our serum data indicating an increased activity of osteoclasts in the Nmp4-KO
mice we compared the number of these cells derived from the bone marrow cultures of the
untreated null and WT animals at 7–8 wks of age. Bone marrow preparations from 3 null
mice and 4 WT mice were cultured in 6-well plates and treated with M-CSF and RANKL as
described in the Materials and Methods section. On average, the Nmp4-KO bone marrow
cultures produced 2-fold more osteoclasts than the WT marrow (null = 1608 ± 87 OC/well;
WT = 877 ± 243 OC/well; p<0.05, data presented as average ± SD). This experiment was
performed twice yielding similar results.
Next we compared the dentin-resorbing activities of the Nmp4-KO and WT osteoclasts.
Mature osteoclasts were obtained from the bone marrow of WT and null mice (n=2–3 mice
per group) as described in the Materials and Methods section. Fully differentiated bone
marrow-derived osteoclasts were re-plated on dentin slices for 48 hrs. The area resorbed was
quantified and normalized for TRAP+ osteoclasts. The Nmp4-KO osteoclasts exhibited a
50% increase in the area resorbed on dentin compared to the WT osteoclasts (null = 154 ±
4.6 % area resorbed/Trap+ cells; WT = 100 ± 13.3 % area resorbed/Trap+ cells; p<0.05,
data presented as average ± SD).
Nmp4-KO mice exhibit a transiently enhanced basal or PTH-stimulated expression of
genes common to osteoblast and osteoclast development
To follow up on our observation that both osteoblast and osteoclast numbers were enhanced
in the null mice, we analyzed femoral RNA harvested during the early phase of PTH
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treatment to evaluate the expression of genes that support the development of both cells.
Animals were treated with intermittent PTH or vehicle for 2 or 3 wks and RNA harvested 1
hr after the last injection. The AP-1 transcription factors c-fos and Fra-2 both exhibited a
significantly enhanced PTH-stimulated increase in the Nmp4-KO mice (genotype ×
treatment interaction) after 2 wks of treatment but these differences were absent after 3 wks
of PTH (Table 3A). Additionally, the transcription factor Nfatc1 was significantly elevated
in the femur of null mice (genotype effect) at the 2 wk time point but was equivalent to the
WT expression at 3 wks of treatment (Table 3A). We also examined the expression of
several genes that mediate osteoblast-osteoclast signaling. Interestingly, the Nmp4-KO mice
showed a significant increase in the expression of EphB4 the receptor for EphrinB2, its
transmembrane ligand, which also showed an elevation in expression that approached
significance but again these differences between the genotypes disappeared at the 3 wk time
point (Table 3A). Both EphB4 and EphrinB2 were responsive to PTH in the null and WT
mice (Table 3A). Interestingly, the Rankl/Opg ratio was diminished in the null mice
compared to WT animals at 2 and 3 wks of treatment, which was significant at the latter
time point (Figure 3A).
Further comparative analysis of femoral gene expression profiles between WT and null mice
at the 2 wk time period failed to show any significant differences between the two genotypes
with one exception (Table 3B). The expression of the pro-survival gene Bcl2 was not
different in WT and null mice and did not respond to hormone in either genotype at this
point in the treatment regimen, however, the expression of Bax, the pro-apoptotic gene was
significantly attenuated in the Nmp4-KO mice (Table 3B). M-csf, its receptor c-fms, and the
osteoclast recruitment cytokine Mcp-1 showed no difference in their expression or PTH-
responsiveness between WT and Nmp4-KO animals (Table 3B). Hormone induced over a
25-fold increase in Nurr1 expression in both WT and null mice (Table 3B). The expressions
of Mkp-1, JunD, Smad3, and Lef1 were modestly but equally elevated with PTH in both
genotypes (Table 3B). Conversely, the mRNA expression of the receptor for advanced
glycation end products (Rage) was attenuated by hormone treatment in both WT and Nmp4-
KO mice (Table 3B).
Next we characterized the expression of genes that support bone formation by analyzing
femoral RNA obtained 24 hr after the last injection of intermittent PTH or vehicle after 2
wks of treatment. We observed a treatment effect, but no genotype effect or genotype ×
treatment interaction for Runx2, Osterix, Col1a1, Alpl and Mmp13, Sost, Bmp2, and Pthr1
mRNA profiles (Table 3B). Intermittent hormone treatment did not impact the expression of
PTH-related peptide (Pthrp) in either genotype (Table 3B).
Our preliminary evaluation of gene expression in the tibia showed that the RNA profiles at 3
wks of treatment were generally similar to those observed for the femur at the same time
point with the exception of Nfatc1, which was still significantly elevated in the tibia of the
null mice (Table 3C). Additionally, the decrease in the Rankl/Opg ratio did not reach
significance in the tibia as demonstrated for the femur (Table 3C).
DISCUSSION
The present data demonstrate that Nmp4/CIZ significantly blunts PTH-stimulated
improvement in cancellous bone throughout the skeleton, that this repression of bone gain is
apparent between 2 wks and 7 wks of hormone treatment, and that Nmp4/CIZ suppresses
osteoclast as well as osteoblast number and activity likely by regulating key transcription
factors critical to the development of both cells. The global impact of Nmp4 on the
trabecular skeleton is in stark contrast to recent studies showing the site-specific effects of
Rage (9) and connexin 43 (10) on PTH-induced cancellous bone improvement.
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Nmp4/CIZ repression of the PTH-mediated increase in trabecular bone was not observed
during the initial 2 wk treatment period; WT and KO mice showed equivalent hormone-
stimulated increases in BMD, BMC, trabecular improvement, and enhanced expression of
numerous genes that support bone formation. At 7 wks of hormone challenge the striking
expansion of the null trabecular compartment had been added and bone histomorphometry
indicated that both the KO and WT mice exhibited a diminished response to PTH consistent
with previous observations on C57BL/6 mice (17). However, starting at 3 wks of hormone
challenge the KO mice exhibited an enhanced and sustained PTH-induced increase in serum
osteocalcin. The significance of the 2–3 wk lag period required for distinguishing the
difference in PTH-stimulated bone formation between the Nmp4-KO and WT mice remains
to be elucidated. Does this delay represent the time necessary to dramatically expand the
null bone-forming osteoblast population? Further histomorphometric analysis at various
time points throughout the treatment regimen is required to address this question.
Of particular significance was our discovery of an osteoclast phenotype in the Nmp4-KO
mouse. The null mice had significantly higher serum CTX; more osteoclasts were recovered
from Nmp4-KO marrow cultures than from WT cultures, and the null osteoclasts were more
active as determined by in vitro resorption of dentin. Interestingly, PTH had a more
significant impact on decreasing the osteoclast-covered bone surface in null mice without
significantly lowering serum CTX, perhaps in part a consequence of the enhanced activity of
the null osteoclasts. Despite the multiple lines of evidence suggesting higher bone resorption
in the untreated nulls these mice are not osteopenic and in fact have a modestly enhanced
skeleton, although the rate of bone accrual from 8–12 wks is marginally slower in the null
animals. Femoral bone marrow-derived osteoblasts from Nmp4/CIZ-deficient mice
exhibited an enhanced alkaline phosphatase expression and formed more mineralized
nodules than wild-type osteoblasts (18), suggesting in vivo that the null osteoblast outpaces
the null osteoclast. Further study is required to determine if there is an increased rate of
remodeling (activation frequency) with a positive bone balance in the untreated mice and if
so, how this is achieved.
Although the in vivo mRNA expression profiles represent a composite of multiple marrow
and bone cell types, the transiently enhanced expression of c-fos, Fra-2, and Nfatc1 in the
null mice may be part of the molecular mechanism contributing to the apparent increased
number of osteoblasts and osteoclasts. Fra-2 plays a significant role in chondrocyte
differentiation and matrix production in embryonic and newborn mice (19) and in regulating
the size of osteoclasts (20).
The contribution of c-Fos to the PTH anabolic response involves both osteoblasts and
osteoclasts; in the former it is part of the immediate-early gene response (21) and as such is
critical for subsequent induction of select target genes. As a key regulator of bone cell
growth and differentiation, c-Fos often interacts with RUNX2 (22). PTH stimulation of
Mmp-13 transcription in osteoblast-like cells requires the cooperative interaction between
the c-Fos•c-Jun AP-1 complex and RUNX2 (23), and Nmp4/CIZ dampens this induction
(8). Consequently, the heightened PTH-stimulated increase in osteoblast c-Fos activity in the
Nmp4-KO mice may boost hormone transcriptional induction of some genes supporting the
anabolic response. The impact of Nmp4/CIZ on c-fos and Fra-2 was specific within the
context of the PTH-induce immediate-early response because we did not observe differences
in other aspects of this gene program including Nurr1, a transcription factor participating in
PTH-mediated osteoblast gene induction (24), Mkp-1, a phosphatase implicated in PTH-
mediated osteoblast cell cycle arrest (25), JunD, involved in osteoblast differentiation (26),
or Smad3 and Lef1, trans-acting proteins involved in coupling the PTH and Wnt signaling
pathways in osteoblasts (27).
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In addition to its role as a PTH-responsive osteoblast transcription factor c-Fos is critical to
osteoclastogenesis and plays a role in supporting the precursor cell’s capacity to undergo
differentiation (28). It fulfills this role in part by mediating the induction of Nfatc1, another
key transcription factor that supports osteoclastogenesis and osteoblast development (29);
the elevation of c-fos mRNA expression in the nulls may ultimately contribute to the
enhanced Nfatc1 expression in these mice. Additionally, c-Fos has multiple and complex
roles in regulating osteoblast-derived signals that regulate osteoclastogenesis and mature
osteoclast activity including the RANKL/OPG signaling axis by governing the
transcriptional activity of the Opg gene in the osteoblast and by activating RANKL target
genes in osteoclasts; c-Fos also activates the IFN-gamma-driven RANKL negative feedback
pathway in the osteoclast (30, 31). The Rankl/Opg ratio was attenuated in the null mice,
which achieved significance in the femur by 3 wks of treatment; perhaps this ultimately
contributed some protective effect from the enhanced osteoclast activity. Nmp4/CIZ had
negligible impact on the mRNA expression of other osteoclastogenic cytokines including
Mcp-1, a cytokine involved in osteoclast recruitment (32), M-csf and its receptor c-fms that
activate the proliferation and survival of osteoclast precursors (33). The significantly
attenuated expression of the pro-apoptotic gene, Bax, in the null mice may contribute to a
longer-lived osteoblast, critical to the PTH-induced anabolic mechanism (5), but further
studies are required to confirm this possibility.
Recent studies with c-fos-null animals indicate that interaction between immature
osteoclasts and pre-osteoblasts may be necessary for an optimal response to intermittent
PTH; specifically the osteoclast precursors support the differentiation of pre-osteoblasts (34,
35; 36). In one potential scenario this coupling is mediated by the bidirectional interaction
between an EphrinB2 ligand on the pre-osteoclast and the EphB4 receptor on the pre-
osteoblast (34, 35). Forward signaling from the osteoclast precursor to the pre-osteoblast
enhances differentiation of the latter whereas reverse signaling suppresses osteoclast
differentiation (35). Therefore, PTH appears to activate both forward and reverse EphrinB-
EphB4 signaling resulting in the enhancement of bone formation and the restraining of
resorption (34). This is consistent with the observed increased expression of EphB4 in the
Nmp4-KO mice and the marginally enhanced ephrinB2 expression in these animals. Future
osteoblast-osteoclast co-culture studies will be needed to investigate the potential impact of
Nmp4/CIZ on the reciprocal regulation of these cells.
We propose that Nmp4/CIZ governs both the osteoblast and osteoclast cellular arms of the
PTH-induced anabolic response by controlling the size, activity, and/or PTH-responsiveness
of these cell populations in part via the modest suppression of several key transcription
factors and receptors critical to the developmental and/or response pathways of both cells.
The complex sequence of molecular and cellular events underlying Nmp4/CIZ regulation of
bone remodeling remains to be elucidated. Nmp4/CIZ has been previously identified as an
attractive potential therapeutic target for treating osteoporosis (37), and the present finding
that this protein not only regulates the osteoblast but also the osteoclast underscores this
assertion.
Acknowledgments
This work was supported by a grant from NIH NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
KIDNEY DISEASES (NIDDK), contract grant number DK053796 (JPB).
References
1. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst
Pharm. 2008; 65:532–539. [PubMed: 18319498]
Childress et al. Page 10
Calcif Tissue Int. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy
with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;
166:1209–1217. [PubMed: 16772249]
3. Childress P, Robling AG, Bidwell JP. Nmp4/CIZ: road block at the intersection of PTH and load.
Bone. 2010; 46:259–266. [PubMed: 19766748]
4. Ahlström M, Lamberg-Allardt C. Rapid protein kinase A-mediated activation of cyclic AMP-
phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res.
1997; 12:172–8. [PubMed: 9041048]
5. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O’Brien CA, Manolagas
SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-
apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is
needed for bone anabolism. J Biol Chem. 2003; 278:50259–50272. [PubMed: 14523023]
6. Robling AG, Childress P, Yu J, Cotte J, Heller A, Philip BK, Bidwell JP. Nmp4/CIZ suppresses
parathyroid hormone-induced increases in trabecular bone. J Cell Physiol. 2009
7. Thunyakitpisal P, Alvarez M, Tokunaga K, Onyia JE, Hock J, Ohashi N, Feister H, Rhodes SJ,
Bidwell JP. Cloning and functional analysis of a family of nuclear matrix transcription factors (NP/
NMP4) that regulate type I collagen expression in osteoblasts. J Bone Miner Res. 2001; 16:10–23.
[PubMed: 11149472]
8. Shah R, Alvarez M, Jones DR, Torrungruang K, Watt AJ, Selvamurugan N, Partridge NC, Quinn
CO, Pavalko FM, Rhodes SJ, Bidwell JP. Nmp4/CIZ regulation of matrix metalloproteinase 13
(MMP-13) response to parathyroid hormone in osteoblasts. Am J Physiol Endocrinol Metab. 2004;
287:E289–96. [PubMed: 15026307]
9. Philip BK, Childress PJ, Robling AG, Heller A, Nawroth PP, Bierhaus A, Bidwell JP. RAGE
supports parathyroid hormone-induced gains in femoral trabecular bone. Am J Physiol Endocrinol
Metab. 2010; 298:E714–E725. [PubMed: 20028966]
10. Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M,
Civitelli R. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice
with an osteoblast-specific deletion of connexin43. J Cell Sci. 2006; 119:4187–4198. [PubMed:
16984976]
11. Cheng S, Sipilä S, Taaffe DR, Puolakka J, Suominen H. Change in bone mass distribution induced
by hormone replacement therapy and high-impact physical exercise in post-menopausal women.
Bone. 2002; 31:126–135. [PubMed: 12110425]
12. Goossens K, Van Poucke M, Van Soom A, Vandesompele J, Van Zeveren A, Peelman LJ.
Selection of reference genes for quantitative real-time PCR in bovine preimplantation embryos.
BMC Dev Biol. 2005:5–27. [PubMed: 15725348]
13. Zhang X, Ding L, Sandford AJ. Selection of reference genes for gene expression studies in human
neutrophils by real-time PCR. BMC Mol Biol. 2005; 6:4. [PubMed: 15720708]
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR.
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the
ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2:595–610.
[PubMed: 3455637]
15. O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M,
Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass
and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008; 3:e2942. [PubMed:
18698360]
16. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R. c-Cbl is downstream of
c-Src in a signalling pathway necessary for bone resorption. Nature. 1996; 383:528–531.
[PubMed: 8849724]
17. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay
R. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels
in mice. J Bone Miner Res. 2002; 17:808–816. [PubMed: 12009011]
18. Morinobu M, Nakamoto T, Hino K, Tsuji K, Shen ZJ, Nakashima K, Nifuji A, Yamamoto H, Hirai
H, Noda M. The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting
Childress et al. Page 11
Calcif Tissue Int. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
bone morphogenetic protein-induced bone formation. J Exp Med. 2005; 201:961–970. [PubMed:
15781586]
19. Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF. The AP1 transcription factor Fra2 is
required for efficient cartilage development. Development. 2004; 131:5717–25. [PubMed:
15509771]
20. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M,
Stewart CL, Amling M, Wagner EF. Osteoclast size is controlled by Fra-2 through LIF/LIF-
receptor signalling and hypoxia. Nature. 2008; 454:221–5. [PubMed: 18548006]
21. Liang JD, Hock JM, Sandusky GE, Santerre RF, Onyia JE. Immunohistochemical localization of
selected early response genes expressed in trabecular bone of young rats given hPTH 1-34. Calcif
Tissue Int. 1999; 65:369–373. [PubMed: 10541762]
22. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone
metabolism. Trends Endocrinol Metab. 2004; 15:60–65. [PubMed: 15036251]
23. D’Alonzo RC, Selvamurugan N, Karsenty G, Partridge NC. Physical interaction of the activator
protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation. J Biol Chem.
2002; 277:816–822. [PubMed: 11641401]
24. Nervina JM, Magyar CE, Pirih FQ, Tetradis S. PGC-1alpha is induced by parathyroid hormone and
coactivates Nurr1-mediated promoter activity in osteoblasts. Bone. 2006; 39:1018–25. [PubMed:
16765661]
25. Qin L, Li X, Ko JK, Partridge NC. Parathyroid hormone uses multiple mechanisms to arrest the
cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem. 2005; 280:3104–11.
[PubMed: 15513917]
26. Wagner EF. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann
Rheum Dis. 2010; 69(Suppl 1):i86–88. [PubMed: 19995753]
27. Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K. Parathyroid
hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology.
2006; 147(5):2583–2590. [PubMed: 16484320]
28. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;
423:337–342. [PubMed: 12748652]
29. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007; 1116:227–
237. [PubMed: 18083930]
30. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K,
Ida N, Wagner EF, Taniguchi T. RANKL maintains bone homeostasis through c-fos-dependent
induction of interferon-beta. Nature. 2002; 416:744–749. [PubMed: 11961557]
31. Fu Q, Jilka RL, Manolagas SC, O’Brien CA. Parathyroid hormone stimulates receptor activator of
NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of
cAMP-response element-binding protein. J Biol Chem. 2002; 277:48868–48875. [PubMed:
12364326]
32. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone
stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J
Biol Chem. 2007; 282:33098–106. [PubMed: 17690108]
33. Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast
differentiation. Immunol Rev. 2009; 231:241–256. [PubMed: 19754901]
34. Luiz de Freitas PH, Li M, Ninomiya T, Nakamura M, Ubaidus S, Oda K, Udagawa N, Maeda T,
Takagi R, Amizuka N. Intermittent PTH administration stimulates pre-osteoblastic proliferation
without leading to enhanced bone formation in osteoclast-less c-fos(−/−) mice. J Bone Miner Res.
2009; 24:1586–1597. [PubMed: 19419301]
35. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. Bidirectional
ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006; 4:111–121. [PubMed:
16890539]
36. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS,
McCauley LK. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid
hormone in bone. Endocrinology. 2005; 146(11):4584–4596. [PubMed: 16081645] Allen MR,
Childress et al. Page 12
Calcif Tissue Int. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Burr DB. Parathyroid hormone and bone biomechanics Clinical Reviews in Bone and Mineral
Metabolism. 2006; 4:259–68.
37. Krane SM. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp
Med. 2005; 201:841–843. [PubMed: 15781576]
Childress et al. Page 13
Calcif Tissue Int. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Childress et al. Page 14
Calcif Tissue Int. Author manuscript; available in PMC 2012 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Disabling Nmp4 enhanced PTH responsiveness of vertebral cancellous bone. Micro-CT-
acquired vertebral (L5) trabecular architecture including (A) BV/TV, %; (B) Conn D,
mm−3; (C) SMI, (D) Tb N mm−1, (E) Tb Th mm, (F) Tb Sp mm was compared between WT
and Nmp4-KO mice that had been treated with intermittent hPTH(1-34) 30μg/kg/day or
vehicle for 7 wks (number of mice/experimental group=11–12). To evaluate the early
hormone response we compared bones from WT and Nmp4-KO mice that had been treated
with intermittent PTH or vehicle for 2 wks using the same experimental design (number of
mice/experimental group=5–7). No improvement was observed after 2 wks of intermittent
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PTH treatment in either the WT or null animals (A–F). There was a genotype effect for BV/
TV, Conn D, SMI, and Tb Th (A, B, C, and E, respectively) consistent with the enhanced
trabecular architecture of the null mice, regardless of treatment. (G) μCT images of vertebral
trabecular bone from WT and Nmp4-KO mice that had been treated with intermittent PTH
or vehicle for 7 wks, Scale bar=1mm. Data is presented as average ± SD. The listed p-values
were determined with a two-factor ANOVA. A Tukey’s HSD post hoc test was used to
determine differences between the treatment groups if a significant genotype × treatment
interaction was indicated.
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Figure 2.
Nmp4-KO mice exhibited an enhanced PTH-induced increase in tibial trabecular bone.
Micro-CT-acquired tibial trabecular architecture including (A) BV/TV, %; (B) Conn D,
mm-3; (C) SMI, (D) Tb N mm-1, (E) Tb Th mm, (F) Tb Sp mm was compared between WT
and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 7 wks
(number of mice/experimental group=8). To evaluate the early hormone response we
compared bones from WT and Nmp4-KO mice that had been treated with intermittent PTH
or vehicle for 2 wks (number of mice/experimental group=7–9). Both genotypes showed
equal hormone-induced improvement of tibial (A) BV/TV, (B) Conn D, (C) SMI, and (E)
Tb Th during the initial 2 wks of treatment. There was a genotype effect for (D) Tb N and
(F) Tb Sp indicating enhanced aspects of tibial architecture in the null mice at 12 wks of age
irrespective of treatment. (G) μCT images of tibial trabecular bone from WT and Nmp4-KO
mice that had been treated with intermittent PTH or vehicle for 7 wks, Scale bar=1mm. The
listed p-values were determined with a two-factor ANOVA. A Tukey’s HSD post hoc test
was used to determine differences between the treatment groups if a significant genotype ×
treatment interaction was indicated.
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Figure 3.
[A] PTH-induced improvements in femoral trabecular architecture were enhanced in Nmp4-
KO mice, after 7 wks of treatment. The femoral tissue sections were obtained from WT and
Nmp4-KO mice treated with intermittent PTH or vehicle for 7 wks (number of mice/
experimental group=5–6). Additionally, animals were administered by intraperitoneal
injection calcein green (20mg/kg) and alizarin red (25mg/kg) 6 days and 3 days before
euthanasia, respectively. [B] Sections were stained for tartarate resistant acid-phosphatase
(TRAP) to evaluate osteoclast number and surface. Histological sections were prepared as
described in the Materials and Methods. Scale bar=200 μm
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Figure 4.
PTH-treated Nmp4-KO mice exhibited strikingly distinct serum chemistries from the WT
animals. Whole blood was collected and serum separated from WT and Nmp4-KO mice
treated with intermittent PTH or vehicle (number of mice/experimental group=6–7) at
baseline just prior initiation of treatment, at 3 wks of treatment, and at 7 wks of treatment.
(A) The raw longitudinal serum osteocalcin concentrations showed no genotype effect, but
revealed a significant treatment effect, a genotype × treatment interaction and a genotype ×
time interaction indicating that the WT and null mice had equivalent baseline values but that
the Nmp4-KO had an enhanced response to hormone and a higher rate of increase over the
experimental time period. (B) The % change data confirmed the raw longitudinal data
revealing a significant genotype effect (higher rate of osteocalcin increase in the nulls), a
treatment effect, and a genotype × treatment interaction over the experimental period. (C)
The raw longitudinal serum CTX concentrations showed a genotype effect, but no
significant treatment effect, no genotype × treatment interaction and no genotype × time
interaction. (D) The % change CTX data showed no significant responsiveness to hormone
treatment in WT and null mice. The listed p-values were determined with a repeated-
measures MANOVA (longitudinal data) or a two-factor ANOVA (% change data).
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